Dr. Antoni Vilaseca Cabo discusses using an intravesical drug delivery system to continuously administer the FGFR inhibitor ...

NCCN has added ImmunityBio's ANKTIVA to its Clinical Practice Guidelines for BCG-unresponsive non muscle invasive bladder cancer with papillary only disease. This update extends recognized use of ...

ImmunityBio Inc. IBRX shares are up Tuesday following the announcement that the National Comprehensive Cancer Network (NCCN) ...

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two "trial in progress" presentations at the 2026 European Association of Urology congress (EAU) in London, UK. These trials investigate ...

ImmunityBio, Inc. remains a Buy, with Anktiva’s regulatory and global expansion driving the investment thesis. Learn more ...

Recommendation is based on peer-reviewed clinical data supporting long-term effectiveness and safety durability in patients with papillary-only disease treated with ANKTIVA plus BCG1.CULVER CITY, ...

ImmunityBio (IBRX) stock jumps as NCCN guidelines recommend an additional use for the company's bladder cancer therapy, ...

ImmunityBio IBRX had an encouraging year in 2025. Last month, the company reported its fourth-quarter and full-year 2025 results, which beat both our earnings and sales estimates — all thanks to the ...

In this episode of From Bench to Bedside and Beyond, Dr. Yaw Nyame and patient Dave Lucas discuss the robotic surgical ...

AstraZeneca AZN announced that the European Commission (EC) has approved its blockbuster cancer drug Imfinzi (durvalumab) as a perioperative treatment for early gastric and gastroesophageal junction ...

AstraZeneca’s Imfinzi in combo with standard-of-care FLOT chemotherapy gets European approval to treat patients with early gastric and gastroesophageal cancers: Cambridge, UK Tu ...

ImmunityBio (IBRX) stock jumped over 6% in premarket trading after the NCCN added ANKTIVA to its bladder cancer guidelines, ...